SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates a potential ETF, with many expecting a significant pump. The discussion centers around the impact of the ETF on DOGE's price, with some users expressing excitement and readiness for a substantial increase. Broader crypto market recovery narratives and meme coin comparisons are also prevalent in the conversation.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending as traders assess whether the recent climb in the $XBI biotechnology index can continue. Some community members are discussing potential resistance levels and debating entry points, while others express frustration with the persistent downtrend and consider cutting losses. Talk centers around market factors including rates, sector rotation, and potential for overall market correction.

Hilton Worldwide Holdings, Inc. engages in the provision of hospitality businesses. It operates through the Management and Franchise, and Ownership segments. The Management and Franchise segment operates hotels of third-party owners. The Ownership segment includes owned, leased, and joint venture hotels. The company was founded by Conrad N. Hilton in 1925 and is headquartered in McLean, VA.

Hilton Worldwide Holdings Inc

Hilton is trending amid analyst target price adjustments and discussion around the hotel and lodging sector's growth. Community members are discussing option activity and potential bullish setups, while noting global expansion and financial soundness. Recent earnings reports and future outlooks are also driving the conversation around the stock.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as biotech stocks experience a sector-wide breakout, fueled by significant buyout activity and increasing AI applications in gene editing and drug discovery. Community discussions highlight the shift from crypto and tech stocks towards biotech, with some eyeing specific price targets and potential shorting opportunities. Others point to technical indicators suggesting it may be overbought.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

$SMCX is trending amid discussions about potential recovery timelines and oversold conditions after a recent downturn, with community members weighing the risks and rewards of leveraged exposure to $SMCI. Traders are actively debating bottom-fishing strategies versus waiting for stronger momentum, while considering the impact of market volatility on the ETF. Some investors express concern about potential decay and management.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as traders react to various actionable trade alerts and discuss the company's growth strategy around its Autoship program. Community members are weighing in on potential price movements, upcoming earnings, and analyst ratings. Some see the recent price action as a buying opportunity while others express concerns about management and unethical behavior.

Sound Group, Inc. is global audio-centric social and entertainment company, which engages in the provision of an audio platform. It focuses on audio entertainment and social networking. The company was founded by Jinnan Lai and Ning Ding in November 2010 and is headquartered in Singapore.

Sound Group Inc - ADR

Sound Group Inc

SOGP is trending as traders discuss potential short squeezes and compare it to other high-flying stocks. Community members are debating the legitimacy of a declared dividend and its impact on the stock's future. Some caution about the risks associated with Chinese ADRs, while others maintain a bullish outlook based on the company's financial performance.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is trending amidst discussions around technical analysis, potential swing trading opportunities, and overall market performance, with some traders closely watching key support and resistance levels. The company's strategic moves into stablecoins and partnerships are also sparking interest. Despite some bearish sentiment and concerns about market lag, many view Visa as a reliable long-term investment, especially with its upcoming ex-dividend date.

Las Vegas Sands Corp. engages in the development of destination properties. It operates through the Macao and Singapore geographical segments. The Macao segment handles the operations of The Venetian Macao, The Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Macao, and Sands Macao. The Singapore segment includes the Marina Bay Sands. The company was founded by Sheldon Gary Adelson in August 2004 and is headquartered in Las Vegas, NV.

Las Vegas Sands Corp

LVS is trending as community members actively discuss options trading strategies, particularly around call options with a $65 strike price. Some traders are pointing to gains on call options, while others debate the future direction of the stock amid broader discussions about the casino and Macau gaming market. Analyst ratings and price target adjustments are also fueling interest in Las Vegas Sands.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals is trending due to positive opinions and potential catalysts, with community members calling it a "sleeper" and highlighting potential for growth in the coming years. The stock is also being discussed in relation to competitor Arrowhead, particularly regarding FDA approvals and market share. Recent analyst upgrades and reiterations with price target increases from firms like Leerink Partners and Needham are contributing to the positive sentiment around IONS.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

Quanterix Corporation (Quanterix or the Company) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of...

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month High - Time to Buy?

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month High - What's Next...

Envestnet Asset Management Inc. Raises Stake in IDEAYA Biosciences, Inc. $IDYA

Envestnet Asset Management Inc. raised its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 12.1% during the second quarter, according to the company in its most recent Form 13F...

Research Analysts Set Expectations for IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Cantor Fitzgerald lifted their FY2025 earnings estimates for IDEAYA Biosciences in a report issued on Thursday, November 13th. Cantor Fitzgerald...

IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Fiera Capital Corp

Fiera Capital Corp boosted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 26.6% during the 2nd quarter, according to the company in its most recent filing with the Securities...

Candriam S.C.A. Cuts Stock Position in IDEAYA Biosciences, Inc. $IDYA

Candriam S.C.A. cut its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 2.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the sixteen analysts that are presently covering the stock, MarketBeat...

Mizuho Boosts IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $46.00

Mizuho increased their target price on IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an "outperform" rating in a report on Tuesday...

IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of IDEAYA Biosciences from a "hold" rating to a "buy" rating in a research note on Sunday...

Leerink Partnrs Has Positive Outlook of IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a research report issued to clients...

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Current Price	$33.99
Prev Close	$33.16
Open	$33.22
Dividend Yield	0.00%
50-Day Moving Average	$29.01
Beta	1.11
Avg. Volume	1.28M
PE Ratio	-18.32

52-Week High	$34.66
52-Week Low	$13.45
Market Capitalization	$2.98B
EPS (Annual)	-$3.36
Price to Book	2.73
Revenue Per Employee	$53,435.11
Enterprise Value/EBITDA	N/A

IDYA
Ideaya Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IDYA News

IDYAIdeaya Biosciences Inc